Spanish cardiac catheterization and coronary intervention registry. 32nd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2022).

INTRODUCTION AND OBJECTIVES: This article presents the annual activity report of the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC) for the year 2022. METHODS: All Spanish centers with catheterization laboratories were invited to participate. Data were collected online and were analyzed by an external company in collaboration with the members of the board of the ACI-SEC. RESULTS: A total of 111 centers participated. The number of diagnostic studies increased by 4.8% compared with 2021, while that of percutaneous coronary interventions (PCI) remained stable. PCIs on the left main coronary artery increased by 22%. The radial approach continued to be preferred for PCI (94.9%). There was an upsurge in the use of drug-eluting balloons, as well as in intracoronary imaging techniques, which were used in 14.7% of PCIs. The use of pressure wires also increased (6.3% vs 2021) as did plaque modification techniques. Primary PCI continued to grow and was the most frequent treatment (97%) in ST-segment elevation myocardial infarction. Most noncoronary procedures maintained their upward trend, particularly percutaneous aortic valve implantation, atrial appendage closure, mitral/tricuspid edge-to-edge therapy, renal denervation, and percutaneous treatment of pulmonary arterial disease. CONCLUSIONS: The Spanish cardiac catheterization and coronary intervention registry for 2022 reveals a rise in the complexity of coronary disease, along with a notable growth in procedures for valvular and nonvalvular structural heart disease.

Inertial Navigation on Extremely Resource-Constrained Platforms: Methods, Opportunities and Challenges.

Inertial navigation provides a small footprint, low-power, and low-cost pathway for localization in GPS-denied environments on extremely resource-constrained Internet-of-Things (IoT) platforms. Traditionally, application-specific heuristics and physics-based kinematic models are used to mitigate the curse of drift in inertial odometry. These techniques, albeit lightweight, fail to handle domain shifts and environmental non-linearities. Recently, deep neural-inertial sequence learning has shown superior odometric resolution in capturing non-linear motion dynamics without human knowledge over heuristic-based methods. These AI-based techniques are data-hungry, suffer from excessive resource usage, and cannot guarantee following the underlying system physics. This paper highlights the unique methods, opportunities, and challenges in porting real-time AI-enhanced inertial navigation algorithms onto IoT platforms. First, we discuss how platform-aware neural architecture search coupled with ultra-lightweight model backbones can yield neural-inertial odometry models that are 31-134× smaller yet achieve or exceed the localization resolution of state-of-the-art AI-enhanced techniques. The framework can generate models suitable for locating humans, animals, underwater sensors, aerial vehicles, and precision robots. Next, we showcase how techniques from neurosymbolic AI can yield physics-informed and interpretable neural-inertial navigation models. Afterward, we present opportunities for fine-tuning pre-trained odometry models in a new domain with as little as 1 minute of labeled data, while discussing inexpensive data collection and labeling techniques. Finally, we identify several open research challenges that demand careful consideration moving forward.

IoT System Based on Artificial Intelligence for Hot Spot Detection in Photovoltaic Modules for a Wide Range of Irradiances.

Infrared thermography (IRT) is a technique used to diagnose Photovoltaic (PV) installations to detect sub-optimal conditions. The increase of PV installations in smart cities has generated the search for technology that improves the use of IRT, which requires irradiance conditions to be greater than 700 W/m2, making it impossible to use at times when irradiance goes under that value. This project presents an IoT platform working on artificial intelligence (AI) which automatically detects hot spots in PV modules by analyzing the temperature differentials between modules exposed to irradiances greater than 300 W/m2. For this purpose, two AI (Deep learning and machine learning) were trained and tested in a real PV installation where hot spots were induced. The system was able to detect hot spots with a sensitivity of 0.995 and an accuracy of 0.923 under dirty, short-circuited, and partially shaded conditions. This project differs from others because it proposes an alternative to facilitate the implementation of diagnostics with IRT and evaluates the real temperatures of PV modules, which represents a potential economic saving for PV installation managers and inspectors.

X-CHAR: A Concept-based Explainable Complex Human Activity Recognition Model.

End-to-end deep learning models are increasingly applied to safety-critical human activity recognition (HAR) applications, e.g., healthcare monitoring and smart home control, to reduce developer burden and increase the performance and robustness of prediction models. However, integrating HAR models in safety-critical applications requires trust, and recent approaches have aimed to balance the performance of deep learning models with explainable decision-making for complex activity recognition. Prior works have exploited the compositionality of complex HAR (i.e., higher-level activities composed of lower-level activities) to form models with symbolic interfaces, such as concept-bottleneck architectures, that facilitate inherently interpretable models. However, feature engineering for symbolic concepts-as well as the relationship between the concepts-requires precise annotation of lower-level activities by domain experts, usually with fixed time windows, all of which induce a heavy and error-prone workload on the domain expert. In this paper, we introduce X-CHAR , an eXplainable Complex Human Activity Recognition model that doesn't require precise annotation of low-level activities, offers explanations in the form of human-understandable, high-level concepts, while maintaining the robust performance of end-to-end deep learning models for time series data. X-CHAR learns to model complex activity recognition in the form of a sequence of concepts. For each classification, X-CHAR outputs a sequence of concepts and a counterfactual example as the explanation. We show that the sequence information of the concepts can be modeled using Connectionist Temporal Classification (CTC) loss without having accurate start and end times of low-level annotations in the training dataset-significantly reducing developer burden. We evaluate our model on several complex activity datasets and demonstrate that our model offers explanations without compromising the prediction accuracy in comparison to baseline models. Finally, we conducted a mechanical Turk study to show that the explanations provided by our model are more understandable than the explanations from existing methods for complex activity recognition.

Localization in Two-Dimensional Quasicrystalline Lattices.

We investigate the emergence of localization in a weakly interacting Bose gas confined in quasicrystalline lattices with three different rotational symmetries: five, eight, and twelve. The analysis, performed at a mean field level and from which localization is detected, relies on the study of two observables: the inverse participation ratio (IPR) and the Shannon entropy in the coordinate space. Those physical quantities were determined from a robust statistical study for the stationary density profiles of the interacting condensate. Localization was identified for each lattice type as a function of the potential depth. Our analysis revealed a range of the potential depths for which the condensate density becomes localized, from partially at random lattice sites to fully in a single site. We found that localization in the case of five-fold rotational symmetry appears for (6ER,9ER), while it occurs in the interval (12ER,15ER) for octagonal and dodecagonal symmetries.

TinyOdom: Hardware-Aware Efficient Neural Inertial Navigation.

Deep inertial sequence learning has shown promising odometric resolution over model-based approaches for trajectory estimation in GPS-denied environments. However, existing neural inertial dead-reckoning frameworks are not suitable for real-time deployment on ultra-resource-constrained (URC) devices due to substantial memory, power, and compute bounds. Current deep inertial odometry techniques also suffer from gravity pollution, high-frequency inertial disturbances, varying sensor orientation, heading rate singularity, and failure in altitude estimation. In this paper, we introduce TinyOdom, a framework for training and deploying neural inertial models on URC hardware. TinyOdom exploits hardware and quantization-aware Bayesian neural architecture search (NAS) and a temporal convolutional network (TCN) backbone to train lightweight models targetted towards URC devices. In addition, we propose a magnetometer, physics, and velocity-centric sequence learning formulation robust to preceding inertial perturbations. We also expand 2D sequence learning to 3D using a model-free barometric g-h filter robust to inertial and environmental variations. We evaluate TinyOdom for a wide spectrum of inertial odometry applications and target hardware against competing methods. Specifically, we consider four applications: pedestrian, animal, aerial, and underwater vehicle dead-reckoning. Across different applications, TinyOdom reduces the size of neural inertial models by 31× to 134× with 2.5m to 12m error in 60 seconds, enabling the direct deployment of models on URC devices while still maintaining or exceeding the localization resolution over the state-of-the-art. The proposed barometric filter tracks altitude within ±0.1m and is robust to inertial disturbances and ambient dynamics. Finally, our ablation study shows that the introduced magnetometer, physics, and velocity-centric sequence learning formulation significantly improve localization performance even with notably lightweight models.

Development of an international standard set of clinical and patient-reported outcomes for children and adults with congenital heart disease: a report from the International Consortium for Health Outcomes Measurement Congenital Heart Disease Working Group.

AIMS: Congenital heart disease (CHD) is the most common congenital malformation. Despite the worldwide burden to patient wellbeing and health system resource utilization, tracking of long-term outcomes is lacking, limiting the delivery and measurement of high-value care. To begin transitioning to value-based healthcare in CHD, the International Consortium for Health Outcomes Measurement aligned an international collaborative of CHD experts, patient representatives, and other stakeholders to construct a standard set of outcomes and risk-adjustment variables that are meaningful to patients. METHODS AND RESULTS: The primary aim was to identify a minimum standard set of outcomes to be used by health systems worldwide. The methodological process included four key steps: (i) develop a working group representative of all CHD stakeholders; (ii) conduct extensive literature reviews to identify scope, outcomes of interest, tools used to measure outcomes, and case-mix adjustment variables; (iii) create the outcome set using a series of multi-round Delphi processes; and (iv) disseminate set worldwide. The Working Group established a 15-item outcome set, incorporating physical, mental, social, and overall health outcomes accompanied by tools for measurement and case-mix adjustment variables. Patients with any CHD diagnoses of all ages are included. Following an open review process, over 80% of patients and providers surveyed agreed with the set in its final form. CONCLUSION: This is the first international development of a stakeholder-informed standard set of outcomes for CHD. It can serve as a first step for a lifespan outcomes measurement approach to guide benchmarking and improvement among health systems.

Sexually dimorphic effects of prolactin treatment on the onset of puberty and olfactory function in mice.

The onset of puberty is associated with the psychophysiological maturation of the adolescent to an adult capable of reproduction when olfactory signals play an important role. This period begins with the secretion of the gonadotropin-releasing hormone (GnRH) from GnRH neurons within the hypothalamus. This is regulated by kisspeptin neurons that express high levels of transmembrane prolactin receptors (PRLR) that bind to and are activated by prolactin (PRL). The elevated levels of serum PRL found during lactation, or caused by chronic PRL infusion, decreases the secretion of gonadotropins and kisspeptin and compromised the estrous cyclicity and the ovulation. In the present work, we aimed to evaluate the effects of either increased or decreased PRL circulating levels within the peripubertal murine brain by administration of PRL or treatment with cabergoline (Cab) respectively. We showed that either treatment delayed the onset of puberty in females, but not in males. This was associated with the augmentation of the PRL receptor (Prlr) mRNA expression in the arcuate nucleus and decreased Kiss1 expression in the anteroventral periventricular zone. Then, during adulthood, we assessed the activation of the mitral and granular cells of the main (MOB) and accessory olfactory bulb (AOB) by cFos immunoreactivity (ir) after the exposure to soiled bedding of the opposite sex. In the MOB, the PRL treatment promoted an increased cFos-ir of the mitral cells of males and females. In the granular cells of male of either treatment an augmented activation was observed. In the AOB, an impaired cFos-ir was observed in PRL and Cab treated females after exposure to male soiled bedding. However, in males, only Cab impaired its activation. No effects were observed in the AOB-mitral cells. In conclusion, our results demonstrate that PRL contributes to pubertal development and maturation of the MOB-AOB during the murine juvenile period in a sex-dependent way.

Access to Therapy for Acute Myeloid Leukemia in the Developing World: Barriers and Solutions.

PURPOSE OF REVIEW: Acute myeloid leukemia (AML) is a costly disease, and its impact is greater in developing countries (DC). We will review the current concept of what are DC, compare the differences in the epidemiology and economic burden of this disease between developed and DC, and finally, analyze the barriers and possible solutions that DC should implement to achieve better results. RECENT FINDINGS: DC is a frequently misunderstood name. The way we use to measure human development is changing, and multidimension metrics better define what are DC. With this in mind, we show the differences in the AML epidemiology and the impact of economic burden in DC. We analyze the barriers to access therapy from a clinician point of view, to show that most DC shared similar challenges but with a diverse healthcare structure. Finally, we provide several possible solutions for a more integrated and timely treatment that allows better results not only in terms of survival but with a better quality of life. The economic burden of AML treatment in DC is high, and the results are poor. It is crucial to face this challenge and propose new treatment approaches to achieve better results.

Magnesium 2000 postmarket evaluation: Guideline adherence and intraprocedural performance of a sirolimus-eluting resorbable magnesium scaffold.

BACKGROUND: The Magmaris bioresorbable magnesium scaffold was successfully tested in in-vitro and in clinical premarket studies. Subsequently the Magmaris postmarket program aimed to review intraprocedural data of at least 2000 patients to assess user preferences, guideline adherence and intraprocedural performance in clinical routine. METHODS: This international multicentre survey encompasses data from 356 hospitals across 45 countries. As part of the certification for Magmaris implantation, each hospital had to complete consecutive post-market evaluation forms of their first 10 commercial Magmaris patients. RESULTS: From June 2016 to May 2018, data on 2018 implantations were collected. Main reasons for selecting Magmaris was patients' life expectancy (67%, n = 1359) and low or not calcified lesions, (67%, n = 1357). Magmaris was successfully deployed in 99% of cases (n = 1995), predilatation was performed in 95% (n = 1922) and post-dilatation in 87% (n = 1756). Physicians rated the overall performance and the pushability as good or very good in 96% of cases (n = 1799). Guide wire friction, trackability, and conformability were rated as good or very good in 94% of cases, and crossability in 93%. The majority of patients were scheduled to receive dual antiplatelet therapy for up to 12 months. CONCLUSION: Generally, implantation guidelines were adhered to and theoretical advantages of the metal scaffold observed in in-vitro tests have translated into practice with good intraprocedural performance outcomes, confirming the controlled roll-out of this novel technology into clinical practice. SUMMARY FOR ANNOTATED TABLE OF CONTENT: The Magmaris 2000 program includes the first commercial cases at each hospital. Overall, data on 2018 implantations were collected. The high rate of pre- and post-dilatation as well as other parameters confirm that generally the implantation guidelines are adhered to and the good intraprocedural performance (rated as good or very good in 96%) confirm the theoretical advantages of a metallic scaffold in practice.

Survival analysis of adult patients with ALL in Mexico City: first report from the Acute Leukemia Workgroup (ALWG) (GTLA).

Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the clonal expansion of hematopoietic lymphoid progenitors. With new target therapies, the survival of adults with ALL has improved in the past few decades. Unfortunately, there are no large ALL patient series in many Latin American countries. Data from the Acute Leukemia Workgroup that includes five Mexico City referral centers were used. Survival was estimated for adult patients with ALL during 2009-2015. In total, 559 adults with ALL were included. The median age was 28 years; 67% were classified into the adolescent and young adult group. Cytogenetic information was available in 54.5% of cases. Of the 305 analyzed cases, most had a normal caryotype (70.5%) and Philadelphia-positive was present in 16.7%. The most commonly used treatment regimen was hyper-CVAD. In approximately 20% of cases, there was considerable delay in the administration of chemotherapy. Primarily refractory cases accounted for 13.1% of patients. At the time of analysis, 26.7% of cases had survived. The 3-year overall survival was 22.1%. The main cause of death was disease progression in 228 (55.6%). Clinical and public health strategies are needed to improve diagnosis, treatment and survivorship care for adult with ALL. This multicentric report represents the largest series in Mexico of adult ALL patients in which a survival analysis and risk identification were obtained.

[High-intensity chemotherapy versus palliative chemotherapy in patients over 60 years with acute myeloid leukemia]. / Quimioterapia intensa frente a quimioterapia paliativa en pacientes con leucemia mieloblástica mayores de 60 años.

BACKGROUND: The use of high-intensity chemotherapy (HIC) for acute myeloid leukemia (AML) in the elderly is controversial. In the present study, it was assessed complete remission and overall survival of AML patients over 60 years treated with HIC or palliative chemotherapy. METHODS: Patients with ECOG ≤ 2 and adequate organic function received HIC with a base of cytarabine for five or seven days, and an anthracycline for three days. If patients achieved complete remission of leukemia, they received one or two cycles of consolidation with cytarabine. Palliative treatment consisted of supported measures and/or oral or intravenous low-dose chemotherapy. RESULTS: Seven patients treated with HIC achieved complete remission versus only one in the palliative group. Only one patient died during HIC treatment. Median survival for HIC-treated patients was 13.25 months, and only 3.35 months for patients treated with palliative therapy (p < 0.05). CONCLUSION: AML patients of 60 years or older, with good performance status (ECOG ≤ 2) and adequate organ function, may benefit from HIC treatment, with better survival, compared with palliative therapy.

Introducción: el tratamiento con quimioterapia intensa (QTI) en pacientes con leucemia mieloblástica (LMA) mayores de 60 años es controversial. En el presente estudio se evaluó la remisión completa y la supervivencia global de pacientes con LMA mayores de 60 años, tratados con QTI o quimioterapia paliativa. Métodos: los pacientes con adecuada función orgánica y ECOG ≤ 2 recibieron QTI a base de citarabina por cinco o siete días más un antracíclico por tres días y terapia de soporte. En caso de lograr remisión completa de la leucemia recibieron uno o dos ciclos de consolidación con citarabina. El tratamiento paliativo consistió en medidas de soporte o quimioterapia oral o intravenosa en dosis bajas. Resultados: del grupo de QTI siete pacientes alcanzaron remisión completa, comparados con uno del grupo de quimioterapia paliativa. La supervivencia global fue de 13.25 meses para los pacientes con QTI y de 3.35 meses para los pacientes de quimioterapia paliativa (p < 0.05). Conclusión: es posible que los pacientes con LMA mayores de 60 años de edad se beneficien de recibir QTI, comparada con la quimioterapia paliativa.

Anticoagulant proteins in a population of Mexican mestizo donors.

BACKGROUND: To determine the activity of antithrombin (AT), protein C (PC), and protein S (PS), as well as the frequency of deficiencies of these proteins in a population of healthy Mexican mestizo blood donors. METHODS: AT, PC, and PS were determined from 1,502 plasma samples of healthy blood donors by using commercial kits in a coagulometer 4 STA (Diagnostica Stago, Asnières, France). RESULTS: A total of 741 women and 761 men were under study. They were divided into age range groups (18-24, 25-34, 35-44, 45-54, and 55-64 years). Activity of AT, PC, and PS was determined. For AT, activity values were specific for each age group according to gender when it had to do with PS, as well as when PC was determined. Frequencies of AT, PC, PS, and activated PC resistance activity deficiencies were obtained from reference levels (RLs) and average levels of this study. Differences were found between both frequencies for AT, PC, and PS, and the average levels obtained were used in this study. The frequencies of the activity deficiencies obtained through the values gotten in this population were: AT, 0.6%; PC, 1.06% (which is higher than the one obtained using the RLs described by commercial kits 0.33% and 0.66%, respectively); and PS, 1% (which is less than 4.5%). CONCLUSIONS: It is necessary to know the characteristics and biological behavior of the coagulation proteins in the Mexican population because the RLs used have been established for populations that are genetically different.

[Primary immune thrombocytopenia in adults in Mexico: national characteristics and the relation to international literature]. / Trombocitopenia inmune primaria (TIP) del adulto en México: características nacionales y su relación con la literatura internacional.

In order to identify the clinical approach of a sample of Mexican hematologists for primary immune thrombocytopenia (ITP) in adults in Mexico, we applied an electronic survey via the internet to identify common practices for the diagnosis and treatment of ITP and draw a comparison between the information from these hematologists with international guidelines or the international literature. The results were analyzed using measures of central tendency. The sample was 21 medical hematologists, predominantly from Mexico City (average age: 51.4 years). A total of 66.7% of the surveyed physicians use international guidelines to make therapeutic decisions, and 43% defined ITP including the numerical concept (< 100 x 10(9)/l). We found some differences between requested clinical exams and tests indicated by the guidelines. In first-line treatment (except emergency), 91% of the participants start with prednisone and 24% use dexamethasone. Danazol is used in persistent ITP by most (41%) of the specialists. In second-line treatment, 67% would indicate splenectomy. Some differences were found between clinical practice of the hematologists in Mexico versus guidelines recommendations.

[Hemorrhagic complications of acute coronary syndromes treatment]. / Complicaciones hemorrágicas del tratamiento de los síndromes coronarios agudos.

Acute coronary syndromes represent a problem of public health. The main goal of the treatment includes early reperfusion and avoidance of recurrent ischemic events. For this, thrombolytic, anticoagulant and antiplatelet drugs are used and, although they clearly improve the ischemic prognosis, are also associated with bleeding. It is now clear that bleeding has a negative impact in the patient's evolution and that its treatment can be also detrimental. It is important to recognize patients at high bleeding risk and to choose the therapy with the best risk-benefit profile. If the patient develops bleeding, it should be identified and treated properly to minimize its negative impact in the patient´s prognosis.

Complicaciones hemorrágicas del tratamiento de los síndromes coronarios agudos / Hemorrhagic complications of acute coronary syndromes treatment

Los síndromes coronarios agudos representan un problema de salud pública. La meta principal del tratamiento incluye la reperfusión temprana cuando está indicada y evitar la recurrencia de eventos isquémicos. Para ello, se utilizan fármacos trombolíticos, anticoagulantes y antiplaquetarios cada vez más potentes que, aunque claramente mejoran el pronóstico isquémico, se acompañan de diversas complicaciones entre las que destacan las hemorrágicas. Cada vez se reconoce con mayor claridad la importancia de estas complicaciones y su impacto negativo en el pronóstico del paciente. Es indispensable reconocer al paciente que tiene un riesgo elevado de desarrollar hemorragia y escoger la terapéutica con el mejor perfil riesgo-beneficio. En caso de que el paciente presente un evento hemorrágico, debe de ser identificado y tratado prontamente de forma adecuada para minimizar su impacto negativo en el pronóstico.

Acute coronary syndromes represent a problem of public health. The main goal of the treatment includes early reperfusion and avoidance of recurrent ischemic events. For this, thrombolytic, anticoagulant and antiplatelet drugs are used and, although they clearly improve the ischemic prognosis, are also associated with bleeding. It is now clear that bleeding has a negative impact in the patient's evolution and that its treatment can be also detrimental. It is important to recognize patients at high bleeding risk and to choose the therapy with the best risk-benefit profle. If the patient develops bleeding, it should be identified and treated properly to minimize its negative impact in the patient's prognosis.

Prognostic value of an abnormal ankle-brachial index in patients receiving drug-eluting stents.

Advanced atherosclerotic disease increases the risk of stent thrombosis after drug-eluting stent (DES) implantation. We aimed to determine if an abnormal ankle-brachial index (ABI) value as a surrogate of atherosclerotic disease and vascular inflammation provides information on 1-year risk of cardiovascular events after DES implantation. A prospective cohort of 1,437 consecutive patients undergoing DES implantation from January through April 2008 in 26 Spanish hospitals was examined. ABI was calculated by Doppler in a standardized manner. Patients were followed to 12 months after the percutaneous coronary intervention to determine total and cardiovascular mortality, stroke, nonfatal acute coronary syndrome (ACS), and new revascularizations. Association of an abnormal ABI value (i.e., ≤ 0.9 or ≥ 1.4) with outcomes was assessed by conventional logistic regression and by propensity-score analysis. Patients with abnormal ABI values (n = 582, 40.5%) in general had higher global cardiovascular risk, the reason for DES implantation was more often ACS, and had a higher rate of complications during admission (heart failure or stroke or major hemorrhage 11.3% vs 5.3%, p <0.001). An abnormal ABI value was independently associated with 1-year total mortality (odds ratio 2.23, 95% confidence interval 1.13 to 4.4) and cardiovascular mortality (odds ratio 2.06, 95% confidence interval 1.04 to 4.22). No independent association was found between an abnormal ABI value and 1-year nonfatal ACS, stroke, and new revascularizations. In conclusion, although an abnormal ABI value was associated with fatal outcomes in patients receiving DESs, no association was found with nonfatal ACS and new revascularizations. A clear relation between abnormal ABI and surrogates of DES thrombosis could not be established.